Skip to content

Straberi Epistamp Needling Treatment For Skin Rejuvenation

Face Study of the Effects of Needling Using the Straberi Epistamp for the Improvement of Fine Lines and Skin Laxity.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04742803
Acronym
ESAA
Enrollment
30
Registered
2021-02-08
Start date
2022-12-23
Completion date
2023-10-12
Last updated
2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Collagen Degeneration, Elastic Skin, Wrinkle

Keywords

microneedling

Brief summary

This pilot study will expand knowledge and application needling using the Epistamp device for the improvement of a new vitalized epidermal layer with new vibrant active cells, supported by more robust collagen and elastin fine lines, deep wrinkles, and collagen production.

Detailed description

This pilot study will expand the knowledge and application needling using the Epistamp device and its benefits for improving the appearance of fine lines, deep wrinkles, and collagen production. The pilot aims to objectively measure skin quality using the Derma Scan, photographs and provide objective data showing improvement by way of the Universal Skincare Institute Blood Flow Scale.

Interventions

DEVICEStraberi Epistamp Microneedling Treatment

The patient's entire face will be treated with the Straberi Epistamp needling device. The following settings will be used as a treatment protocol. Needle length between .02- 1.55 mm

Sponsors

Lavish Beauty
CollaboratorUNKNOWN
Universal Skincare Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Derma Scan showing aging including skin texture, wrinkles, brown spots, and pores. * Patients willing to sign informed consent. * Patients willing to be photographed and video documented * Patients willing to consent to 3 months of treatment

Exclusion criteria

* History of eczema in the treatment area; psoriasis and any other chronic skin conditions * History of actinic (solar) keratosis in the treatment area; * History of hemophilia * History of diabetes * The presence of raised moles, warts on the targeted area. * Collagen vascular diseases or cardiac abnormalities * Blood clotting problems * Active bacterial or fungal infection * Facial melanosis * Malignant tumors * Immunosuppression * Use of blood thinners or prednisone * Corticosteroids within two weeks of the procedure * Chronic liver disease * Porphyria or other skin diseases. * Patient not willing to sign informed consent. * TCA peels in the last 5 weeks * Subject currently has moderate to severe acne on the face. * Microneedling within the last 6 months * Subject has an active infection. * Subject has a history of a bleeding disorder * Subject has a history of keloidal tendency * Subject has received ablative or non-ablative laser treatments in the previous 6 months. * Subject has taken Accutane within the previous 3 months.

Design outcomes

Primary

MeasureTime frameDescription
The Global Aesthetic Improvement Scale (GAIS)6 monthsThe Global Aesthetic Improvement Scale (GAIS) is a 5-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator 5 point scale ranging from 1 to 5 with 5 = The appearance has worsen compared with the original condition and 1 = Excellent corrective results investigator.

Secondary

MeasureTime frameDescription
Overall Skin improvement assessed by Derma Scan6 monthsThe Derma Scan System utilizes two special lighting systems (RGB +UV) and smart skin analyzer software that allows two images (before and after care) to be compared side by side, which can be used to detect the changes in skin.
Photographs6 monthsDigital imaging device using a grid background with controlled lighting and setting to grade acne scar improvement on a quartile grading scale(1 = 1% to 25%, 2 = 26 to 50%, 3 = 51 to 75%, 4 = \>76% improvement).
To evaluate the impact on the quality of life (DLQI)6 monthsThe Dermatology Life Quality Index questionnaire (DLQI) is 10 questions were asked to the patients and score is 0-3 for each question. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.
Wrinkle Severity Rating Scale (WSRS)6 monthsThe Wrinkle Severity Rating Scale assesses the presence and severity of wrinkles at rest in a rating scale from 0 to 4, where 0 means no visible wrinkles, 1 means minimal wrinkles, 2 means shallow wrinkles, 3 means moderately deep wrinkles and 4 means very deep wrinkles.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026